Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06694805 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

A Phase 3 study of HIV Infections, sponsored by ViiV Healthcare.

Recruiting
Registry status
Phase 3
Development phase
332
Enrollment target
20
Study locations

NCT06694805 is a Phase 3 study of HIV Infections that is actively recruiting participants, run by ViiV Healthcare. The registered enrollment target is 332 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06694805, a Phase 3 study of HIV Infections, is actively recruiting participants, sponsored by ViiV Healthcare.

RECRUITING
Registry status
Phase 3
Development phase
332 participants
Enrollment target
20
Study locations

Study Summary

This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also consider feedback from patients on their experience with this treatment.

Conditions Studied

HIV Infections

Interventions

  • DRUG CAB LA + RPV LA
  • DRUG Oral ART

Study Locations (20)

California

  • GSK Investigational Site - Beverly Hills
  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Los Angeles

Florida

  • GSK Investigational Site - Jacksonville
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Sarasota
  • GSK Investigational Site - West Palm Beach

Georgia

  • GSK Investigational Site - Atlanta
  • GSK Investigational Site - Decatur
  • GSK Investigational Site - Macon

Illinois

  • GSK Investigational Site - Chicago
  • GSK Investigational Site - Chicago
  • GSK Investigational Site - Chicago

Colorado

  • GSK Investigational Site - Aurora
  • GSK Investigational Site - Denver

Alabama

  • GSK Investigational Site - Birmingham

Connecticut

  • GSK Investigational Site - New Haven

Delaware

  • GSK Investigational Site - Newark

Trial Details

FieldValue
Enrollment Target 332 participants
Start Date 2024-12-02
Est. Completion 2028-06-19
Phase Phase 3

Sponsor

ViiV Healthcare

182 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06694805

The ClinicalTrials.gov registry entry for NCT06694805 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (25% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which CAB LA + RPV LA is the first listed.

NCT06694805 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06694805 about?

NCT06694805 is a clinical study titled "A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1". This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also consider feedback from patients on their experience with this tre...

What is the current status of trial NCT06694805?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 332 participants. The study started on 2024-12-02. Estimated completion is 2028-06-19.

What conditions does trial NCT06694805 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT06694805?

The interventions under investigation include: CAB LA + RPV LA (DRUG), Oral ART (DRUG).

Who is sponsoring clinical trial NCT06694805?

This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06694805 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.